Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca/BARDA In Antibiotics Deal; $170m Potential

This article was originally published in Scrip

Executive Summary

AstraZeneca has entered into a public-private partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop new antibacterials intended to address biothreat pathogens, in addition to antibiotic resistance, under a "portfolio" approach, which will allow the U.S. government funds to be steered away from a product that proves to be unsuccessful early on in the R&D process to other promising candidates.


Related Companies